Alto Neuroscience (NYSE:ANRO) Stock Price Down 7.3% - What's Next?

Key Points

• Alto Neuroscience shares fell 7.3% to about $31.57 in Thursday trading, with volume roughly 41% above average. The company’s market capitalization is approximately $1.23 billion.
• Analyst sentiment remains broadly positive, with eight Buy ratings, two Holds and one Sell. The consensus rating is Moderate Buy, with an average price target of $37.25.
• Alto reported a quarterly loss of $0.65 per share, beating estimates for a $0.73 loss. Analysts expect a full-year loss of approximately $2.68 per share as the clinical-stage biotechnology company continues developing precision treatments for neuropsychiatric disorders.

Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report)'s share price dropped 7.3% on Thursday . The stock traded as low as $31.86 and last traded at $31.5660. Approximately 540,236 shares traded hands during mid-day trading, an increase of 41% from the average session volume of 381,970 shares. The stock had previously closed at $34.07.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on ANRO shares. HC Wainwright lifted their price target on Alto Neuroscience from $50.00 to $55.00 and gave the stock a "buy" rating in a research note on Monday, August 17th. Wall Street Zen raised shares of Alto Neuroscience from a "sell" rating to a "hold" rating in a research note on Saturday, August 29th. Zacks Research upgraded shares of Alto Neuroscience from a "strong sell" rating to a "hold" rating in a report on Thursday, August 20th. Wedbush upped their price target on shares of Alto Neuroscience from $24.00 to $26.00 and gave the company a "neutral" rating in a report on Thursday, August 13th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Alto Neuroscience in a research report on Wednesday, July 29th. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $37.25.

Alto Neuroscience Trading Down 7.7%

The business has a 50-day moving average of $30.39 and a 200 day moving average of $25.18. The stock has a market cap of $1.23 billion, a PE ratio of -13.00 and a beta of 1.13. The company has a debt-to-equity ratio of 0.07, a quick ratio of 14.85 and a current ratio of 14.85.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.73) by $0.08. Equities research analysts predict that Alto Neuroscience, Inc. will post -2.68 EPS for the current fiscal year.

Hedge Funds Weigh In On Alto Neuroscience

Several institutional investors have recently added to or reduced their stakes in the business. GK Wealth Management LLC acquired a new stake in shares of Alto Neuroscience in the second quarter worth approximately $226,000. California State Teachers Retirement System acquired a new position in shares of Alto Neuroscience in the 2nd quarter valued at $251,000. Balyasny Asset Management L.P. purchased a new stake in shares of Alto Neuroscience during the 4th quarter valued at $198,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Alto Neuroscience during the 4th quarter worth $221,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in shares of Alto Neuroscience during the 4th quarter worth $304,000.

About Alto Neuroscience

Alto Neuroscience NYSE: ANRO is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto's proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.